Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?
Elizabeth Marie GavioliNerli GuardadoFarah HaniffNouran DeiabEtty ViderPublished in: Microbial drug resistance (Larchmont, N.Y.) (2021)
Cystic fibrosis (CF) is associated with frequent pulmonary exacerbations and the need for novel antibiotics against antimicrobial resistance. Cefiderocol is a newly approved therapeutic option active against a variety of multidrug resistant (MDR) bacteria such as gram-negative species commonly encountered by CF patients. This review describes the potential role of cefiderocol against Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex. Cefiderocol is a potential therapeutic option for MDR pathogens with minimum inhibitory concentrations (MICs) of ≤4 mg/L. Due to the lack of in vivo evidence in the CF population, cefiderocol may be utilized in patients in which alternative options are lacking due to MDR organisms or rapid pulmonary decline.
Keyphrases
- gram negative
- multidrug resistant
- cystic fibrosis
- pseudomonas aeruginosa
- drug resistant
- acinetobacter baumannii
- klebsiella pneumoniae
- end stage renal disease
- antimicrobial resistance
- lung function
- pulmonary hypertension
- ejection fraction
- newly diagnosed
- chronic obstructive pulmonary disease
- prognostic factors
- chronic kidney disease
- climate change
- escherichia coli
- intensive care unit
- air pollution